Filing Flows

Filing Flows › Companies › Mesa Laboratories › Report card

Mesa Laboratories earnings report card

Every report on file against what analysts and the company itself expected, and what the stock did

Beat rate3 of 4 reports beat the EPS estimate

Mesa Laboratories (MLAB) beat the analysts' EPS estimate in 3 of its last 4 reports (75%), by +9.4% on average. On report days the stock moved 8.4% in either direction on median (largest 13.7%), rising 75% of the time; after a beat it rose 67% of the time. Next report: Nov 9, 2026, analysts expect EPS $2.24.

Beat rate75% of 4
Average surprise+9.4%
Median move on the day±8.4%
Rose on the day75%
Next reportNov 9, 2026

Report by report

QuarterReportedEPS est.EPS reportedSurpriseGAAP EPSRevenue reportedStock, the dayvs market
Q1 FY27Aug 10, 2026$2.55$1.30-49.1%$0.49$60.1M+8.4%+8.7%
Q4 FY26May 27, 2026$1.39$1.83+31.5%—$63.7M-2.9%-3.4%
Q3 FY26Feb 3, 2026$1.47$1.76+19.9%$0.65$65.1M+13.7%+15.0%
Q2 FY26Nov 6, 2025$1.56$2.11+35.2%$0.45$60.7M+2.4%+3.4%

Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.

Charts

Mesa Laboratories: EPS reported against the estimateMesa Laboratories: EPS reported against the estimateEstimateReported$1.56$2.11Q2 FY26$1.47$1.76Q3 FY26$1.39$1.83Q4 FY26$2.55$1.30Q1 FY27
Latest (Q1 FY27): Estimate $2.55, Reported $1.30.
MLAB: the stock's move on each report dayMLAB: the stock's move on each report dayQ1 FY27+8.4%Q4 FY26-2.9%Q3 FY26+13.7%Q2 FY26+2.4%
Close to close around the report, from the daily price history.

The earnings-day move

Over 4 reports the stock moved 8.4% on median on the day (close to close), the largest move 13.7%.

After a beat the stock rose 67% of the time (3 beats).

The next report: what to expect → Mesa Laboratories: every quarter →

Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.